The data was collected using the supplied MRM method which contains two transitions (qualifier and quantifier) per compound, with associated preconfigured parameters for cone voltage and collision energies for 178 compounds. The three negative control reference urines (Basis-line U, Blankcheck, and Negative Control) and four positive control reference urines (C2, S10, DAU HC2, and DCT -25%) containing certified levels of analytes, were assayed using the method described above. The data was automatically processed using the TargetLynx Application Manager, following a slight increase in the area threshold reject parameter, as a result of the increased response of the TQ-S micro. Screening results were compared for equivalence to the data obtained from the Xevo TQD platform.
A number of compounds were detected in the negative control reference urines on both platforms, i.e. caffeine and other substances associated with over-the-counter medications, which are routinely detected in urine screens.
For the certified positive control reference urines, both platforms detected the same number of expected compounds in the S10 reference urine. The Xevo TQ-S micro also found the same analytes as the Xevo TQD in the C2 and DAU HC2 urine samples, but in addition was able to detect α-hydroxyalprazolam in the C2 urine and lorazepam in the DAU HC2 urine.
Additional sensitivity for the benzodiazepines was also confirmed through analysis of the ACQ Science DCT -25% sample. Figure 2 details five additional benzodiazepines which were detected using the Xevo TQ-S micro. This commercial reference urine has certified levels of analytes at a concentration equivalent to 25% lower than the maximum cut-off concentration currently recommended by the European Workplace Drug Testing Society (EWDTS) for confirmation tests in urine;5 the benzodiazepines detected here are present in this urine at 75 ng/mL.
